Aerie pharmaceuticals reports q3 adjusted loss per share of $0.86

Aerie pharmaceuticals reports third quarter 2019 financial results, updates full-year 2019 guidance and provides business update.q3 gaap loss per share $1.09.q3 earnings per share estimate $-0.80 -- refinitiv ibes data.q3 adjusted loss per share $0.86.sees fy 2019 revenue $61 million to $66 million.fy2019 revenue view $69.0 million -- refinitiv ibes data.qtrly revenue $18.5 million versus $7.3 million.q3 revenue view $17.7 million -- refinitiv ibes data.aerie - lowering fy2019 net revenue guidance, reflecting recent volume trends & expectations in upcoming holiday season.
AERI Ratings Summary
AERI Quant Ranking